No “they” don’t. The phase 3 shows almost no real change in symptoms vs control groups…1.6 vs 1.2 change in score (out of 18) on Alzheimer’s battery used (CDRSB) and over an 18 months— (calling that a 27% change in symptom progression is disingenuous- yes it’s “statistically significant” but in reality that’s the difference between a 1/2 point in scoring on some domain of the battery over a yr and a 1/2 of treatment) and nowhere is it suggested in the actual data that there are “19 months more of independent living”— maybe the stock prospectus says that though! It’s a crock of shit. This is a media blitz. Anyway don’t take my word the study is published if you can sift through the bias in it

It doesn’t do anything… so for yrs we’ve noted increased amyloid plaque buildup with Alzheimer’s. And so there was a line of reasoning (widely accepted) suggesting the buildup may be part of a causal relationship with cognitive decline. This medicine does what it is what targeted to do- but it turns out amyloid buildup may not play the role we thought (as the medicine doesn’t do anything for the actual symptoms). So it’s cool in that it makes us think about lines of inquiry being off the mark, but I wouldn’t prescribe it to any of my Alzheimer’s pts.-because again it doesn’t actually help

China’s rail system is a $3 trillion dollar time bomb that is about to cripple their economy… I’m all for high speed rail in the us and massive federal scale mass transit, but China is literally the worst example you could have provided for a model here..

The avg Muscovite makes about $24k a yr. I don’t think the market will be too hot…